Company: ABBV
Filing Date: 2025-02-14
Form Type: 10-K
Source: 0001551152-25-000020
Chunk: 341

Company: AbbVie Inc.
Filing Date: 2025-02-14
Form: 10-K
Item: Item 8
Chunk 341
---
 observable in the market; and•Level 3—Valuations using significant inputs that are unobservable in the market and include the use of judgment by the company's management about the assumptions market participants would use in pricing the asset or liability.

2024 Form 10-K   |  80

The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the consolidated balance sheet as of December 31, 2024:Basis of fair value measurement(in millions)TotalQuoted prices in active markets for identical assets (Level 1)Significant other observable inputs (Level 2)Significant unobservable inputs (Level 3)AssetsCash and equivalents$5,524 $5,179 $345 $— Money market funds and time deposits10 — 10 — Debt securities33 — 33 — Equity securities98 70 28 — Foreign currency contracts313 — 313 — Total assets$5,978 $5,249 $729 $— LiabilitiesInterest rate swap contracts$231 $— $231 $— Foreign currency contracts35 — 35 — Financing liability328 — — 328 Contingent consideration21,666 — — 21,666 Total liabilities$22,260 $— $266 $21,994  The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the consolidated balance sheet as of December 31, 2023:Basis of fair value measurement(in millions)TotalQuoted prices in active markets for identical assets (Level 1)Significant other observable inputs (Level 2)Significant unobservable inputs (Level 3)AssetsCash and equivalents$12,814 $6,223 $6,591 $— Money market funds and time deposits10 — 10 — Debt securities26 — 26 — Equity securities111 86 25 — Foreign currency contracts66 — 66 — Total assets$13,027 $6,309 $6,718 $— LiabilitiesInterest rate swap contracts$293 $— $293 $— Foreign currency contracts203 — 203 — Contingent consideration19,890 — — 19